SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549
 

FORM 8-K
____________________________

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 11, 2012
____________________________

Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)
___________________________

Delaware
(State or other jurisdiction of Incorporation)

001-12215
  
16-1387862
(Commission File Number)
 
  
(I.R.S. Employer Identification No.)
Three Giralda Farms
Madison, NJ  07940
  
07940
(Address of principal executive offices)
  
(Zip Code)
     
(973) 520-2700
(Registrant’s telephone number, including area code)
     

___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction a.2. below):
 
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
    
Item  5.07.  Submission of Matters to a Vote of Security Holders

   
(a)
The Annual Meeting of Shareholders of the Quest Diagnostics Incorporated (the “Company”) was held on May 11, 2012.
   
(b)
The following nominees for the office of director were elected for terms expiring at the 2015 Annual Meeting of Shareholders, by the following votes:

   
For
    
Against
    
Abstain
    
Broker Non-Vote
  
                         
Jenne K. Britell, Ph.D.
     121,187,796       9,552,582       346,533       7,757,571  
                                 
Gail R. Wilensky, Ph.D.
     128,361,318       2,428,389       297,204       7,757,571  
                                 
John B. Ziegler
     120,021,499       10,737,938       327,474       7,757,571  

 
The following persons also continue as directors:
   
 
John C. Baldwin, M.D.
 
William F. Buehler
 
Gary M. Pfeiffer
 
Timothy M. Ring
 
Stephen H. Rusckowski
 
Daniel C. Stanzione, Ph.D.

The amendments to the Company’s Amended and Restated Employee Long-Term Incentive Plan were approved by the following votes:

For
  
Against
  
Abstain
  
Broker Non-Vote
108,270,993
  
22,466,599
  
349,031
  
7,757,571

 
The ratification of the appointment of the Company’s independent registered public accounting firm for 2012 was approved by the following votes:

For
  
Against
  
Abstain
          
137,029,463
  
1,391,238
  
423,781
    
      

The advisory resolution to approve executive compensation was approved by the following votes:

For
  
Against
  
Abstain
  
Broker Non-Vote
             
80,806,470
  
46,363,185
  
3,917,256
  
7,757,571
   
 
 

 
 
 
 
      
The shareholder proposal regarding the classified board of directors was approved by the following votes:

For
  
Against
  
Abstain
  
Broker Non-Vote
             
119,988,626
  
4,884,962
  
3,452,621
  
7,757,571


Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 
  May 16, 2012  
     
  QUEST DIAGNOSTICS INCORPORATED
         
         
  By:    /s/ William J. O’Shaughnessy, Jr.  
      William J. O’Shaughnessy, Jr.  
      Assistant General Counsel and Secretary